Results 191 to 200 of about 50,964 (281)

Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair

British Journal of Pharmacology, Volume 183, Issue 11, Page 2947-2968, June 2026.
Background and Purpose Endometriosis is a chronic, hormone‐dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, its impact on lesion regression is limited, possibly due to apoptosis resistance and ...
Yujie Peng, Meng Zhang, Libo Zhu, Wenqiang Qian, Jingjing Yan, Huidi Jiang, Yu Xin, Ying Zhang, Dongli Sun, Weidong Fei, Mengdan Zhao   +10 more
wiley   +1 more source

Comprehensive Profiling Reveals Sialyl‐Tn Upregulation and Prognostic Value in Prostate Cancer

Pathology International, Volume 76, Issue 6, June 2026.
This study utilises a novel antibody (L2A5) to comprehensively monitor sialyl‐Tn antigen (sTn) expression levels in clinical prostate cancer tissues. We reveal sTn is expressed in 44% of prostate tumours and find prostate cancer patients with high sTn levels have significantly poorer survival times.
Kirsty Hodgson, Libby Blencoe, Erin Smith, Aswini Sasikumar, Ziqian Peng, Margarita Orozco‐Moreno, Richard Beatson, Paula A. Videira, Jennifer Munkley   +8 more
wiley   +1 more source

Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Ozay ZI, Jo Y, Gebrael G, Ostrowski M, Mathew Thomas V, Li H, Graf RP, Roy S, Maughan BL, Guha A, Riaz IB, Antonarakis ES, McKay RR, Agarwal N, Swami U.   +14 more
europepmc   +1 more source

Novel Immunotherapeutic Strategies for Castration-Resistant Prostate Cancer: Mechanisms and Clinical Advances. [PDF]

Curr Issues Mol Biol
Xia X, Xia Z, Yu L.
europepmc   +1 more source

Prognostic value of PSMA PET-derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. [PDF]

Cancer Imaging
Atasever T, Babacan GB, Ekinci ÖB, Buyukkuscu A, Uslu BS, Kabaca FZY, Atcı MM, Karyagar S, Ertürk K, Çelik E.   +9 more
europepmc   +1 more source

Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone. [PDF]

Cardiooncology
Bryce AH, Nimke D, Young C, Shao Q, Rozario N, Kamdar P, Ivanova J, Varghese I, Touya M.   +8 more
europepmc   +1 more source

Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer. [PDF]

Bioact Mater
Di J, Lee W, Xu Y, Kong H, Zhou F, Xu J, Chen X, Lao YH, Shao D, Xie X, Yao H, Tao Y, Li M.   +12 more
europepmc   +1 more source

Nicotinamide N-methyltransferase as a therapeutic target in taxane-resistant castration-resistant prostate cancer. [PDF]

Cell Death Discov
Cevatemre B, Karyemez E, Bulut I, Syed H, Gönen M, Baykal AT, Bagci-Onder T, Acilan C.   +7 more
europepmc   +1 more source

ISEV2026 Abstract Book

Journal of Extracellular Vesicles, Volume 15, Issue S1, June 2026.
wiley   +1 more source

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Li C, Madan RA, Lee MJ, Lee S, Sato N, Rastogi S, Shrestha R, Aragon-Ching JB, Goswami M, Donahue RN, Cordes LM, Baj A, Seo CCY, Terrigino NT, Bright JR, Hennigan ST, King IM, Trostel SY, Fenimore JM, Liu Y, Calzone KA, Schlom J, Gulley JL, Dahut WL, Figg WD, Sowalsky AG, Lee JM, Karzai F.   +27 more
europepmc   +1 more source